In addition to the aforementioned IFN-dampening chemicals and CPA to enhance OV replication, large-scale approaches identified the most promising drugs for ICB for combination therapy [134], best candidates for OV-arming [135,136,137], and other factors required for increased OV replication [138], as well as the better cancer mutations for optimal OV-based therapy [139]. Here, IFNA1 is linked to cancer.